Correspondence 0001193125-24-201304 from CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc.
Date: Aug. 15, 2024 · CIK: 0001501989 · Accession: 0001193125-24-201304
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281433
Letter
CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
August 15,
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Tamika Sheppard
Re: CytomX Therapeutics, Inc.
Registration Statement on Form S-3 (Registration No. 333-281433)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 19, 2024, or as soon as practicable thereafter.
Thank you for your assistance in this matter.
Very truly yours,
CytomX Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 August 15, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tamika Sheppard Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-281433) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 19, 2024, or as soon as practicable thereafter. Thank you for your assistance in this matter. Very truly yours, CytomX Therapeutics, Inc. By: /s/ Lloyd A. Rowland Lloyd A. Rowland Senior Vice President and General Counsel CC: Sean A. McCarthy, CytomX Therapeutics, Inc. Chris Ogden, CytomX Therapeutics, Inc. Mark V. Roeder, Latham & Watkins LLP [Signature Page to CytomX Therapeutics, Inc. Acceleration Letter]